StoryPartnership
M42 makes strategic investment in Juvenescence and forms AI therapeutics partnership
Abu Dhabi health company M42 made a strategic investment in Juvenescence and formed a partnership to jointly develop AI-enabled therapeutics for age-related diseases, announced at Abu Dhabi Global Health Week. The collaboration combines M42's genomics, biobanking, and clinical trial infrastructure with Juvenescence's AI-enabled drug discovery technology.
- M42 brings genomics, biobanking with 900,000+ samples, and clinical trial infrastructure; Juvenescence contributes AI-enabled discovery.
- Partnership focuses on novel drug discovery for cognition, cardio-metabolism, immunity, and cellular repair.
- Reflects Abu Dhabi's ambition to establish itself as a global hub for AI-driven longevity science and biotechnology innovation.